BioLineRx (BLRX) Net Cash Flow (2013 - 2025)

BioLineRx's Net Cash Flow history runs 13 years deep, the most recent figure standing at -$4.8 million for Q4 2025.

• On a quarterly basis, Net Cash Flow fell 433.03% year-over-year to -$4.8 million in Q4 2025; TTM through Dec 2025 was -$7.7 million, a 225.59% decrease from a year earlier, with the FY2025 full-year figure at -$7.7 million, down 225.59% from the prior year.
• Net Cash Flow declined to -$4.8 million in Q4 2025 per BLRX's latest filing, from $651000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $3.9 million in Q2 2024 and bottomed at -$4.8 million in Q4 2025.
• The 5-year median for Net Cash Flow is -$1.1 million (2022), against an average of -$676400.0.
• Across the five-year window, Net Cash Flow soared 218.34% in 2024 and plunged 433.03% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$1.3 million in 2021, then tumbled by 85.42% to -$2.5 million in 2022, then tumbled by 48.46% to -$3.7 million in 2023, then jumped by 139.25% to $1.4 million in 2024, then plunged by 433.03% to -$4.8 million in 2025.
• Per Business Quant, the three latest BLRX Net Cash Flow figures stand at -$4.8 million (Q4 2025), $651000.0 (Q3 2025), and -$2.3 million (Q2 2025).